{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:01:25Z","timestamp":1743998485163,"version":"3.40.3"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ando.2025.101682","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T07:53:02Z","timestamp":1736322782000},"page":"101682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Key data from the 2024 European Thyroid Association Congress. Graves\u2019 orbitopathy: Old recipes or new cuisine?"],"prefix":"10.1016","volume":"86","author":[{"given":"Miriam","family":"Ladsous","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5391-7582","authenticated-orcid":false,"given":"Philippe","family":"Caron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2025.101682_bib0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ando.2024.01.001","article-title":"Key data from the 2023 European Thyroid Association congress: breakthrough advances in the treatment of Graves\u2019 orbitopathy","volume":"85","author":"Ladsous","year":"2024","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2025.101682_bib0105","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.ando.2023.05.007","article-title":"The key data from the 2022 European Thyroid Association congress: toward personalized treatment of Graves\u2019 orbitopathy","volume":"84","author":"Abeillon-du Payrat","year":"2023","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2025.101682_bib0110","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ando.2021.02.001","article-title":"Treatment of moderate to severe orbitopathy: current modalities and perspectives","volume":"82","author":"Bouzehouane","year":"2021","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2025.101682_bib0115","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ando.2020.01.003","article-title":"Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican, population","volume":"81","author":"Ceballos-Mac\u00edas Jos\u00e9","year":"2020","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2025.101682_bib0120","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101682_bib0125","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101682_bib0130","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s40618-022-01862-y","article-title":"Sirolimus as a second-line treatment for Graves\u2019 orbitopathy","volume":"45","author":"Lanzolla","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2025.101682_bib0135","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/IOP.0000000000001876","article-title":"Inhibition of fibrotic contraction by sirolimus (Rapamycin) in an ex vivo model of thyroid eye disease","volume":"37","author":"Roos","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ando.2025.101682_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ando.2025.101682_bib0145","doi-asserted-by":"crossref","first-page":"e33626","DOI":"10.1371\/journal.pone.0033626","article-title":"Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ando.2025.101682_bib0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12890-018-0626-4","article-title":"Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells","volume":"18","author":"Molina-Molina","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.ando.2025.101682_bib0155","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/IOP.0b013e3180500d57","article-title":"Rapamycin for treatment of refractory dysthyroid compressive optic neuropathy","volume":"23","author":"Chang","year":"2007","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ando.2025.101682_bib0160","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41433-019-0340-3","article-title":"Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves\u2019 orbitopathy","volume":"33","author":"Roos","year":"2019","journal-title":"Eye"},{"key":"10.1016\/j.ando.2025.101682_bib0165","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.101.OP-13-07","article-title":"Long-term outcome of Graves\u2019 orbitopathy following treatment with sirolimus","author":"Comi","year":"2024","journal-title":"Endocrine Abstracts"},{"key":"10.1016\/j.ando.2025.101682_bib0170","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-024-02470-8","article-title":"Long-term outcome of Graves\u2019 orbitopathy following treatment with sirolimus","author":"Comi","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2025.101682_bib0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.101682_bib0180","article-title":"Efficacy of teprotumumab on medical and surgical resistant don","author":"Carretti","year":"2024","journal-title":"Endocrine Abstracts"},{"key":"10.1016\/j.ando.2025.101682_bib0185","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy\u2014Results from a phase I clinical trial","volume":"96","author":"Furmaniak","year":"2022","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2025.101682_bib0190","article-title":"GENSCI098-A potent TSHR antagonist antibody for the treatment of TED","author":"Sun","year":"2024","journal-title":"ETA"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625000010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625000010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T08:36:48Z","timestamp":1743928608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426625000010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0003426625000010"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2025.101682","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Key data from the 2024 European Thyroid Association Congress. Graves\u2019 orbitopathy: Old recipes or new cuisine?","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2025.101682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101682"}}